Spindle Cell Metaplastic Breast Carcinoma with Leiomyoid Differentiation: A Case Report by Conrad, Claudius et al.
Case Report · Kasuistik
Breast Care 2011;6:230–233 Published online: June 14, 2011
DOI: 10.1159/000329330
Claudius Conrad, M.D. Ph.D.
Harvard Medical School and Harvard Stem Cell Institute
Department of Surgery, Massachusetts General Hospital
55 Fruit Street, GRB-425, Boston, MA 02114, USA
Tel. +617 72-62803, Fax -43499
cconrad1@partners.org, www.massgeneral.org/gensurg/
© 2011 S. Karger GmbH, Freiburg
1661–3791/11/0063-0230$38.00/0
Accessible online at: 
www.karger.com/brc
Fax +49 761 4 52 07 14
Information@Karger.de
www.karger.com
BreastCare
Spindle Cell Metaplastic Breast Carcinoma  
with Leiomyoid Differentiation: A Case Report
Claudius Conrada Diane L. Millerb Christina Kaiserc 
Karl-Walter Jauchd Hanno Nieße Ralf Hussc,f
aDepartment of Surgery, Massachusetts General Hospital,
bTufts University School of Medicine, Boston, MA, USA
cInstitute of Pathology, University of Munich,
dDepartment of Surgery, University of Munich-Grosshadern,
eDepartment of Surgery, University of Munich,
fRoche Diagnostics GmbH, Penzberg, Germany
Schlüsselwörter
Karzinom · Leiomyoid · Metaplasie · Phylloidtumor · 
Spindelzelle
Zusammenfassung
Hintergrund: Metaplastische Mammakarzinome sind 
eine seltene aber eigenständige Entität innerhalb der 
Gruppe der undifferenzierten invasiven Karzinome. Die-
se Entität macht weniger als 0.5% aller Mammakarzinome 
aus und beinhaltet Elemente epithelialer (duktaler), mes-
enchymaler und intermediärer Differenzierungsformen. 
Es existieren Berichte von metaplastischen Karzinomen 
mit chondroider, squamöser, osseöser und spindelzel-
liger Differenzierung. Fallbericht: Wir beschreiben den 
klinischen Verlauf einer 52-jährigen Patientin mit der 
ungewöhnlichen Histopathologie eines Spindelzellkarzi-
noms der Brust. Außerdem werden ein Überblick über 
die Literatur und Empfehlungen bezüglich der Diagnose 
und Behandlung gegeben. Die Patientin war ursprüng-
lich mit einem schnell wachsenden Knoten in der Brust 
in einem externen Krankenhaus vorstellig geworden, wo 
ein maligner Phylloidtumor diagnostiziert wurde. 11 Mo-
nate nach der primären Therapie wurde sie erneut mit 
einem lokalen, subkutanen Rezidiv vorstellig. Später kam 
ein lokales Rezidiv des metaplastischen Karzinoms in der 
Brustwand hinzu. Nach eingehender histopathologischer 
Untersuchung wurde ein Mammakarzinom mit Spindel-
zell-Metaplasie und Leiomyoid-Differenzierung diagnos-
tiziert, was bisher noch nie beschrieben wurde. Schluss-
folgerungen: Überlappende morphologische Eigenschaf-
ten können zur Fehlinterpretation bzw. Unterdiagnose 
metaplastischer Karzinome führen. Die Prognose ist je-
doch mit der von häufiger auftretenden Arten von Ade-
nokarzinomen der Mamma vergleichbar.
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Summary
Background: Metaplastic carcinoma of the breast is a 
rare but distinct entity within the group of undifferenti-
ated invasive carcinomas. This entity accounts for less 
than 0.5% of all breast cancers and contains elements of 
epithelial (ductal), mesenchymal, and intermediate 
forms of differentiation. Of these metaplastic carcino-
mas, there have been reports of chondroid, squamous, 
osseous, and spindle differentiation. Case Report: We 
describe the clinical course of a 52-year-old female pa-
tient with an unusual histopathology of a spindle cell 
carcinoma of the breast, discuss the literature, and rec-
ommend an approach to diagnosis and treatment. The 
patient initially presented to an outside hospital with a 
rapidly growing breast mass that was originally diag-
nosed as a malignant phylloides tumor. She presented 
11 months after the primary treatment with a local sub-
cutaneous relapse. She later developed a local relapse of 
her metaplastic carcinoma in the chest wall. Extensive 
histopathological analysis lead to the diagnosis of a 
spindle cell metaplastic breast carcinoma with leiomyoid 
differentiation, which has not been described previously. 
Conclusions: Overlap in morphology can lead to a mis-
interpretation or underdiagnosis of metaplastic carcino-
mas. However, the prognosis is similar to more common 
types of breast adenocarcinoma.
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Introduction
The term metaplastic describes a histopathological phenotype 
that is unusual. Many tumors are identified as metaplastic, 
indicating that the tumor deviates from the native tissue of 
the organ where it was found. For spindle cell metaplastic car-
cinoma, glandular epithelium transforms into nonglandular 
mesenchymal tissue [1]. 
After the introduction of the term metaplasia by Huvos et 
al. [2], many terms such as carcinosarcoma were established to 
describe the metaplastic component of the tumor. However, 
even today, the terminology concerning metaplastic carci-
noma is inadequate, since there is no clear-cut definition of 
the inclusion criteria. Further, whenever considering the diag-
nosis of a metaplastic tumor entity, a local collision of 2 sepa-
rate tumor entities needs to be considered as well.
The difficulties concerning spindle cell carcinomas of the 
breast are not limited to the histopathological diagnosis. The 
most common clinical presentation is a large palpable mass [3], 
however, tumor sizes reported so far vary amongst studies. 
One study from Edinburgh reports tumor sizes between 2.2 and 
10 cm [4], while patients evaluated in a South Korean study 
had palpable masses with a mean tumor size of 4.2 cm [5].
There is little data on patients who were detected by 
mammographic screening, and presently, there is no known 
specific mammographic characteristic of metaplastic cancer. 
Mammographic findings reported in the literature have 
varied between ill defined and spiculated masses. A retro-
spective analysis of patients with metaplastic carcinoma 
(n = 16) found 15 masses and 1 clustered calcification without 
an associated mass [5]. In only 11 of the 15 cases diagnosed 
with mammography could an association be made by using 
ultrasound. On B-mode sonography, there was complex inter-
nal echogenicity with solid and cystic components in 6 of the 
16 cases in a study by Park et al. [5] and 1 of 8 cases in a study 
by Günhan-Bilgen [3].
Metastasis is rare, but when dissemination occurs, it is 
suggested that it bypasses the lymph nodes [1]. However, 
Khan et al. [6] demonstrated in a case series that spindle cell 
carcinomas of the breast commonly metastasize to the axillary 
lymph nodes and that omitting node sampling may result in 
under-staging .
Due to the rarity of the tumor, there are no common guide-
lines for its treatment. Recent case series as well as large 
studies with more than 180 patients recognized the lack of 
adequate treatment options and demonstrated the aggressive 
nature of this carcinoma [7–10].
b
Case Report
One and a half years prior to presentation to our department, a 53-year-
old patient discovered a rapidly growing, pea-sized lump in the inner 
lower quadrant of her left breast. Ultrasound and mammography re-
vealed a tumor 3.3 cm in size (BI-RADS IV). The patient underwent 
a bioptic analysis of the tumor with subsequent operative extirpation. 
Histopathological diagnosis of the biopsy was ‘malignant phylloides 
tumor.’ The tumor was Ki67 20%, G3 differentiated, HER2/neu-negative 
(HERCEP score 0), and estrogen and progesterone receptor-negative 
(immune reactive score 0). Due to infiltration of the skin, it was necessary 
to resect a substantial part of the skin overlying the tumor. An expert 
breast pathologist contacted for reference confirmed a diagnosis of 
spindle cell metaplastic carcinoma. An axillary dissection was performed, 
revealing 12 lymph nodes free of tumor. Final staging at this point was 
pT2, G3, pN0, pM0, R0. One month later, the patient was referred for 
radiotherapy planning. The recommendation was to perform 50/2.0 Gy 
thoracic wall radiation with sparing of the axilla and local electron boost 
3×2 Gy. At this point, no chemotherapy was performed.
Eleven months after the initial mastectomy, the patient presented with 
a lump in the area of the scar from the primary mastectomy. Multislice 
computed tomography (CT) imaging revealed a tumor 4.5 × 2.0 cm in size 
extending from the thoracic wall with streaky branches into the subcuta-
neous tissue (fig. 1). The tumor bordered directly on the cortex of the 
adjacent ribs without apparent infiltration. Staging revealed no metasta-
sis. The patient was transferred to our department where an extirpation 
of the tumor with resection of part of the 6th rib was performed. After the 
operation, the patient received a chemotherapeutic treatment with 6 cy-
cles of epirubicin (75 mg/m2) and taxotere (75 mg/m2), which was toler-
ated without significant side effects.
One month after completion of her chemotherapeutic regimen, the 
patient developed metastasis to both lungs. The extensive progression 
of the lung metastasis under epirubicin and taxotere limited the therapeu-
tic options of the oncologist to a palliative monotherapy of ifosfamide 
(6,000 mg days 1 and 2; 5,000 mg day 3). The goals of this treatment were 
prolongation of survival and avoidance of tumor-associated side effects. 
The patient tolerated the monotherapy with ifosfamide well, so after 
1 cycle of ifosfamide, cisplatin (50 mg days 4 and 5) was added. Unfortu-
nately, the patient progressed to develop brain metastasis and died 1 year 
after her tumor recurrence.
Fig. 1. Magnetic resonance imaging of the tumor relapse 11 months after 
the primary presentation.
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HER2/neu. Based on the pathological analysis, the tumor diagnosis was 
confirmed as metaplastic carcinoma and not a phylloides tumor.
Discussion
Spindle cell carcinomas of the breast are a rare entity within 
the group of metaplastic carcinomas. They can pose great 
diagnostic and therapeutic problems to pathologists and 
surgeons. The metaplastic morphology makes it hard to 
diagnose, and the high rate of local relapse challenges 
surgeons as well as oncologists. Presently, there is no clear 
understanding whether spindle cell metaplastic carcinoma of 
the breast is of epithelial or mesenchymal origin. The complex 
histopathogenesis makes it necessary to perform additional 
IHC studies to exclude metaplastic carcinoma when the diag-
nosis of fibromatosis, low-grade mesenchymal tumor, or even 
phylloides tumor is made on standard H and E preparations.
In this report, we have described the clinical course and the 
pathology of a spindle cell metaplastic carcinoma with an 
unusual leiomyoid differentiation. This rare event is often 
misdiagnosed as phylloides tumor because it shares common 
morphologic and immunophenotypical features with sarcoma. 
Since metastasis is rare in phylloides tumors but often occurs 
in spindle cell metaplastic carcinomas, the correct histopatho-
logical diagnosis is crucial. Therefore, emphasis needs to be 
placed on screening of local relapse as well as metastasis [11]. 
We recommend that IHC analysis should include a keratin 
panel (MNF 116, CK 14, 34 bE12), SMA, vimentin, and AE1/
AE3 [12, 13]. However, although these markers clearly lend 
themselves to narrowing the diagnosis, they are not diagnostic 
for metaplastic carcinoma. HER2/neu and estrogen receptor 
status should also be evaluated for treatment options, how-
ever, spindle cell carcinomas rarely express these hormone 
receptors [14]. Mammography is not useful in the diagnosis of 
spindle cell carcinoma of the breast but is useful for the detec-
tion of a breast mass. Metastasis to the axilla is rare in low-
grade spindle cell carcinoma and is uncommon in high-grade 
tumors [5, 6]. 
The options in the management of a relapse remain very 
limited. In the case described above, epirubicin combined 
with taxotere had minimal success. The role of ifosfamide 
should also be considered as an alternative approach to treat-
ment. Other recommendations include wide local excision or 
mastectomy without axillary dissection [15], protein kinase 
inhibitors [14], anti-epidermal growth factor receptor drugs 
[16], or adjuvant radiotherapy [11], however, literature on 
current treatment guidelines is sparse due to the rarity of this 
disease.
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Pathology
Originally the mass was diagnosed as a phylloides tumor by the patholo-
gist in a community hospital. However, the tissue was sent to a reference 
pathologist for additional breast pathology, and a final diagnosis of 
‘spindle cell metaplastic carcinoma with leiomyoid differentiation’ was 
reported. This diagnosis was based on light microscopy as well as immu-
nophenotyping (fig. 2). The tumor showed spindle-shaped cells with a 
myxoid amorphic matrix. Moreover, there were areas with glandular 
complexes that can be ascribed to glandular and small ductal elements 
without atypia. Those areas did not appear to be part of the tumor and 
can be attributed to ductal hyperplasia of the epithelium. Within the 
tumor, there were areas with bigger polygonal cells rather than spindle-
shaped cells. This finding suggests that this tumor was a metaplastic carci-
noma rather than a true sarcoma. To confirm the suspicion of a metaplas-
tic carcinoma, a defined set of immunohistochemistry (IHC) staining was 
performed. Staining against panzytokeratin AE1/AE2 was negative ini-
tially, however, using the antibody MNF 116 we saw staining of about 
10% of the spindle cells. The majority of the cells also demonstrated a 
strong expression of smooth muscle antigen. Desmin was negative on all 
slides. 
The material harvested from the operation at our hospital (relapse 
thoracic wall) was evaluated as a connective tissue tumor with heteroge-
neous cell populations. The fraction of cell proliferation was 20% of epi-
theloid cells and 5% of the remaining cells. Like the primary tumor, the 
material in this sample was dominated by atypical spindle-shaped cells 
with a hyperbasophilic nucleus with vacuoles. The nuclei varied a great 
deal in shape as well as in size. In 10 high-power fields (HPF), 11 mitoses 
were found. IHC showed positivity for panzytokeratin, p63, vimentin, and 
smooth muscle actin. CK18, CD31, CD34, BCL 2, estrogen receptor, and 
progesterone receptor were negative, and there was no overexpression of 
Fig. 2. Histology of the spindle cell carcinoma (hematoxylin/eosin 
staining): a spindle-shaped cells with myxoid amorphic matrix and 
hyperbasophilic nucleus, b vacuoles and mitosis dominating the 
aspect; Immunophenotyping: c staining against pancytokeratin, d p63, 
e vimentin, and f smooth muscle actin (original magnification × 400).
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